DaVita Inc. (NYSE:DVA) Stock Position Lessened by Korea Investment CORP

Korea Investment CORP reduced its stake in shares of DaVita Inc. (NYSE:DVA) by 15.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,019 shares of the company’s stock after selling 4,600 shares during the quarter. Korea Investment CORP’s holdings in DaVita were worth $3,742,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of DVA. MML Investors Services LLC increased its position in shares of DaVita by 1.3% during the 3rd quarter. MML Investors Services LLC now owns 5,300 shares of the company’s stock valued at $869,000 after purchasing an additional 68 shares during the period. Exchange Traded Concepts LLC boosted its stake in DaVita by 8.3% during the fourth quarter. Exchange Traded Concepts LLC now owns 891 shares of the company’s stock valued at $133,000 after buying an additional 68 shares in the last quarter. Impact Partnership Wealth LLC grew its holdings in DaVita by 3.7% during the fourth quarter. Impact Partnership Wealth LLC now owns 1,941 shares of the company’s stock worth $290,000 after acquiring an additional 70 shares during the period. Contravisory Investment Management Inc. raised its position in DaVita by 1.2% in the fourth quarter. Contravisory Investment Management Inc. now owns 6,082 shares of the company’s stock worth $910,000 after acquiring an additional 73 shares in the last quarter. Finally, Nilsine Partners LLC lifted its holdings in DaVita by 0.8% in the 4th quarter. Nilsine Partners LLC now owns 11,160 shares of the company’s stock valued at $1,669,000 after acquiring an additional 92 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE:DVA opened at $151.82 on Wednesday. The company has a market cap of $12.15 billion, a P/E ratio of 14.14, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company’s fifty day moving average is $156.77 and its two-hundred day moving average is $157.44. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Barclays upped their price target on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a report on Tuesday, February 18th. StockNews.com lowered DaVita from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Sanford C. Bernstein set a $184.00 target price on DaVita in a report on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.